# Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26
Canonical URL: https://biopharmsignal.com/news/MDXH/mdxhealth-to-present-fourth-quarter-and-full-year-2025-financial-results-and-cor-ee7072dc
Ticker: MDXH
Company: MDxHealth
Source: MDxHealth
Published: 2026-02-12 22:00 EST
## Summary

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 Company to Host Conference Call with Live...

## Article Body
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET

IRVINE, California – February 12, 2026 ( GlobeNewswire ) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, February 26, 2026.

| Title: | Mdxhealth Presents Fourth Quarter and Full Year 2025 Financial Results and Corporate Update Conference Call and Webcast |
| --- | --- |
| Date: | February 26, 2026 |
| Time: | 4:30pm ET/ 22:30 CET |
| Conference Call D ial-in Details: | United States : 1-844-825-9789 Int’l: 1-412-317-5180 Belgium : 0800 38 961 United Kingdom : 0800 279 9489 |
| Conference ID: | 10206764 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1753070&tp_key=27bce7d4de |

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.

About Mdxhealth

Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation), exosomal and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Waltham, Massachusetts and Plano, Texas. European headquarters are in Herstal, Belgium. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information: info@mdxhealth.com

LifeSci Advisors (IR & PR) John Fraunces Managing Director Tel: +1 917 355 2395 Jfraunces@lifesciadvisors.com

mdx
## Recent Company News
- 2026-07-24 20:59 EST — [Mdxhealth Announces Receipt of Nasdaq Notification Regarding  Minimum Market Value of Listed Securities Deficiency](https://biopharmsignal.com/news/MDXH/mdxhealth-announces-receipt-of-nasdaq-notification-regarding-minimum-market-valu-cf439d90) — Source: MDxHealth
- 2026-07-02 20:00 EST — [Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency](https://biopharmsignal.com/news/MDXH/mdxhealth-announces-receipt-of-nasdaq-notification-regarding-minimum-bid-price-d-bdf178d6) — Source: MDxHealth
- 2026-06-29 12:00 EST — [Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial](https://biopharmsignal.com/news/MDXH/mdxhealth-announces-peer-reviewed-publication-of-oxford-gps-prompt-study-in-euro-d931d4ac) — Source: MDxHealth
- 2026-05-13 20:00 EST — [Mdxhealth Reports Q1-2026 Results](https://biopharmsignal.com/news/MDXH/mdxhealth-reports-q1-2026-results-52a85fa2) — Source: MDxHealth
- 2026-04-30 20:00 EST — [Mdxhealth to Release First Quarter 2026 Financial Results on May 13](https://biopharmsignal.com/news/MDXH/mdxhealth-to-release-first-quarter-2026-financial-results-on-may-13-70772180) — Source: MDxHealth
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)